Sangamo Therapeutics, Inc.
SGMO
$0.56
-$0.02-2.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 74.64% | 75.78% | 62.01% | 45.96% | -25.78% |
| Total Depreciation and Amortization | -47.95% | -54.23% | -57.82% | -58.43% | -30.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -84.52% | -86.66% | -89.67% | -87.82% | -46.59% |
| Change in Net Operating Assets | 190.22% | 184.89% | 102.06% | 93.88% | 95.14% |
| Cash from Operations | 79.29% | 78.46% | 70.14% | 50.58% | 27.05% |
| Capital Expenditure | 94.63% | 97.56% | 98.74% | 89.27% | 80.40% |
| Sale of Property, Plant, and Equipment | 1,336.22% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -100.00% | -79.48% | -58.67% | -13.62% |
| Cash from Investing | -98.62% | -98.90% | -75.56% | -53.35% | 3.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 104.94% | -40.34% | 85.37% | -35.95% | -71.38% |
| Repurchase of Common Stock | -182.95% | -326.68% | 6.54% | 23.22% | 31.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 101.03% | -49.88% | 94.52% | -36.53% | -72.19% |
| Foreign Exchange rate Adjustments | 2,429.03% | -122.65% | -238.10% | 71.49% | -107.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 129.74% | -17.39% | 94.05% | 54.51% | 20.31% |